Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Canada
  4. Toronto Stock Exchange
  5. ProMIS Neurosciences, Inc.
  6. Summary
    PMN   CA74346M1095

PROMIS NEUROSCIENCES, INC.

(PMN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancials 
Quotes 5-day view   Delayed Quote. Delayed Toronto Stock Exchange
06/14/2021 06/15/2021 06/16/2021 06/17/2021 06/18/2021 Date
0.23(c) 0.22(c) 0.23(c) 0.22(c) 0.215(c) Last
257 246 310 152 206 664 89 697 324 101 Volume
-8.00% -4.35% +4.55% -4.35% -2.27% Change
More quotes
Financials
Sales 2019 0,00 M 0,00 M 0,00 M
Net income 2019 -7,40 M -5,93 M -5,93 M
Net cash position 2019 1,70 M 1,37 M 1,37 M
P/E ratio 2019 -4,59x
Yield 2019 -
Sales 2020 0,00 M 0,00 M 0,00 M
Net income 2020 -5,66 M -4,54 M -4,54 M
Net cash position 2020 1,07 M 0,86 M 0,86 M
P/E ratio 2020 -3,96x
Yield 2020 -
Capitalization 65,8 M 52,7 M 52,7 M
EV / Sales 2019 37 534x
EV / Sales 2020 15 614x
Nbr of Employees -
Free-Float 81,2%
More Financials
Company
ProMIS Neurosciences Inc, formerly Amorfix Life Sciences Ltd, is a Canada-based development-stage biotech company. The Company discovers and develops precision therapeutics with companion diagnostics for early detection and treatment of neurodegenerative diseases, in particular Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS). The assays are developed using its technologies, Epitope Protection and... 
Sector
Biotechnology & Medical Research
Calendar
06/30 | 12:00pmShareholder meeting
More about the company
All news about PROMIS NEUROSCIENCES, INC.
06/09PROMIS NEUROSCIENCESá : congratulates Biogen on FDA accelerated approval of aduc..
AQ
06/08PROMIS NEUROSCIENCESá : congratulates Biogen on FDA accelerated approval of aduc..
PU
06/07PROMIS NEUROSCIENCESá : up 30% on FDA Approval of Biogen's Aducanumab
MT
06/03PROMIS NEUROSCIENCESá : Files preliminary short form base shelf prospectus
PU
05/27PROMIS NEUROSCIENCESá : appoints renowned scientist, Dr. David Wishart as Chief ..
PU
05/25UPDATE : ProMIS Neurosciences Up 8.1% As Says initiated Commercialization of COV..
MT
05/25PROMIS NEUROSCIENCESá : Says initiated Commercialization of COVID-19 Serology As..
MT
05/25PROMIS NEUROSCIENCES BRIEF : Says initiated Commercialization of COVID-19 Serolo..
MT
05/25PROMIS NEUROSCIENCESá : initiates commercialization of COVID-19 serology assay
AQ
05/24PROMIS NEUROSCIENCESá : re-initiates path to IND for PMN310 with producer cell l..
AQ
05/21PROMIS NEUROSCIENCESá : re-initiates path to IND for PMN310 with producer cell l..
AQ
05/14PROMIS NEUROSCIENCESá : Announces First Quarter 2021 Results
AQ
05/12ProMIS Neurosciences appoints renowned neuroscientist, Dr. Rudolph Tanzi, as ..
GL
03/31PROMIS NEUROSCIENCESá : Announces Fiscal Year 2020 Results
PU
03/23PROMIS NEUROSCIENCESá : Completes US$7M Financing with Distinguished Group of Bo..
AQ
More news
News in other languages on PROMIS NEUROSCIENCES, INC.

- No features available -

More news
Chart PROMIS NEUROSCIENCES, INC.
Duration : Period :
ProMIS Neurosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROMIS NEUROSCIENCES, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Managers and Directors
NameTitle
Elliot Goldstein President, Chief Executive Officer & Director
Daniel E. Geffken Chief Financial Officer
Eugene Williams Executive Chairman
Neil R. Cashman Director & Chief Scientific Officer
William W. Wyman Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PROMIS NEUROSCIENCES, INC.115.00%53
GILEAD SCIENCES, INC.14.33%83 541
WUXI APPTEC CO., LTD.24.70%63 775
REGENERON PHARMACEUTICALS11.35%55 705
BIONTECH SE160.57%51 304
VERTEX PHARMACEUTICALS-20.52%48 628